Insights

Cutting-edge Biomarkers MiraDx utilizes cutting-edge genetic research to develop novel genetic biomarkers based on microRNA biology, offering a unique opportunity for personalized cancer treatment solutions.

Advanced Diagnostic Test The validation of MiraDx's PROSTOX ultra test in predicting long-term side effects from radiation therapy for prostate cancer presents a compelling sales opportunity in the field of molecular diagnostics and personalized medicine.

Global Collaborations With numerous collaborations across academic and industry sectors worldwide, MiraDx is well-positioned to expand its reach and market presence, offering potential partnership opportunities for sales growth.

Tech-Driven Approach MiraDx leverages a diverse tech stack, including RSS, WordPress, MySQL, and Google APIs, demonstrating a tech-driven approach that aligns with the current market trends, enriching opportunities for technology-related sales engagements.

Competitive Landscape In a market with established players like QIAGEN, Bio-Rad Laboratories, and Thermo Fisher Scientific Inc, MiraDx's innovative biomarker solutions set it apart, creating space for competitive positioning and differentiation to drive sales in the biotechnology research industry.

Similar companies to MiraDx

MiraDx Tech Stack

MiraDx uses 8 technology products and services including RSS, WordPress, MySQL, and more. Explore MiraDx's tech stack below.

RSS
Content Management System
WordPress
Content Management System
MySQL
Database
Google Font API
Font Scripts
jQuery Migrate
Javascript Libraries
Google Tag Manager
Tag Management
Genesis theme
Web Platform Extensions
Nginx
Web Servers

Media & News

MiraDx, Inc. is developing PROSTOX ultra.
MiraDx, a molecular diagnostics company advancing personalized medicine through novel germline biomarkers, announced a groundbreaking study published in the journal Clinical Cancer Research, validating previous findings that its PROSTOX ultra test can predict long-term side effects from radiation therapy for prostate cancer, prior to starting treatment.
Apr 08, 2025 | www.diagnosticsworldnews.com

MiraDx's Email Address Formats

MiraDx uses at least 1 format(s):

MiraDx Email Formats	Example	Percentage
First@miradx.com	John@miradx.com	46%
FLast@miradx.com	JDoe@miradx.com	4%
First@miradx.com	John@miradx.com	46%
FLast@miradx.com	JDoe@miradx.com	4%

Frequently Asked Questions

Where is MiraDx's headquarters located?

MiraDx's main headquarters is located at 11601 Wilshire Blvd 105 Los Angeles, CA 90025 US. The company has employees across 1 continents, including North America.

What is MiraDx's phone number?

You can contact MiraDx's main corporate office by phone at

+1-424-387-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is MiraDx's stock symbol?

MiraDx is a publicly traded company; the company's stock symbol is LMDXW.

What is MiraDx's official website and social media links?

MiraDx's official website is miradx.com and has social profiles on LinkedIn.

How much revenue does MiraDx generate?

As of June 2025, MiraDx's annual revenue reached $1.8M.

What is MiraDx's SIC code NAICS code?

MiraDx's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does MiraDx have currently?

As of June 2025, MiraDx has approximately 23 employees across 1 continents, including North America. Key team members include Chief Financial Officer: K. S.Vice President Marketing: R. B.Vice President Of Business Development: K. D.. Explore MiraDx's employee directory with LeadIQ.

What industry does MiraDx belong to?

MiraDx operates in the Biotechnology Research industry.

What technology does MiraDx use?

MiraDx's tech stack includes RSSWordPressMySQLGoogle Font APIjQuery MigrateGoogle Tag ManagerGenesis themeNginx.

What is MiraDx's email format?

MiraDx's email format typically follows the pattern of . Find more MiraDx email formats with LeadIQ.

When was MiraDx founded?

MiraDx was founded in 2010.

MiraDx

Biotechnology ResearchCalifornia, United States11-50 Employees

MiraDX was founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers, based on microRNA biology. Our mission is to apply these novel biomarkers to improve personalized cancer treatment. 
 
We have been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. We are able to apply our biomarkers to the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do.  

Through worldwide collaborations MiraDX has advanced this class of biomarkers to the forefront of personalized therapy, and has numerous collaborations across both academic and industry. We encourage you to learn more by visiting our website at MiraDX.com, as well as through visiting our sister non-profit, MiraKind, at MiraKind.org.

Company Overview

Headquarters: 11601 Wilshire Blvd 105 Los Angeles, CA 90025 US
Phone number: +1-424-387-****
Website: miradx.com
SIC Code: 8731 - Commercial Physical and Biological Research
Stock Symbol: LMDXW
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2010
Employees: 11-50